HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment Journal Article


Authors: Guo, A.; Lu, P.; Lee, J.; Zhen, C.; Chiosis, G.; Wang, Y. L.
Article Title: HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment
Abstract: Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of B cells in the hematopoietic system and lymphoid tissues. Although inhibitors targeting the B-cell receptor (BCR) pathway have been successful in the treatment of the disease, the underlying mechanisms leading to BCR over-activity in CLL are not fully understood. In this study, we found that HSP90, a highly conserved molecular chaperone, is overexpressed in CLL compared with resting B cells. HSP90 overexpression is accompanied by the overexpression of several BCR kinases including LYN, spleen tyrosine kinase, Bruton tyrosine kinase and AKT. Chemical and immune-precipitation demonstrated that these BCR constituents are present in a multi-client chaperone complex with HSP90. Inhibition of HSP90 with PU-H71 destabilized the BCR kinases and caused apoptosis of CLL cells through the mitochondrial apoptotic pathway. Further, PU-H71 induced apoptosis in the presence of stromal co-culture or cytoprotective survival signals. Finally, genetic knockdown of HSP90 and its client AKT, but not BTK, reduced CLL viability. Overall, our study suggests that the chaperone function of HSP90 contributes to the over-activity of the BCR signaling in CLL and inhibition of HSP90 has the potential to achieve a multi-targeting effect. Thus, HSP90 inhibition may be explored to prevent or overcome drug resistance to single targeting agents.
Keywords: proteins; targets; lymphoma; mutations; chronic lymphocytic-leukemia; mechanisms; antitumor-activity; btk; ibrutinib resistance; inhibitor ibrutinib
Journal Title: Oncogene
Volume: 36
Issue: 24
ISSN: 0950-9232
Publisher: Nature Publishing Group  
Date Published: 2017-06-15
Start Page: 3441
End Page: 3449
Language: English
ACCESSION: WOS:000403340700008
DOI: 10.1038/onc.2016.494
PROVIDER: wos
PUBMED: 28114285
PMCID: PMC5645670
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Gabriela Chiosis
    279 Chiosis